Your Messages Inbox
Your Article Summary
See Latest ArticlesActive Biotech Presents Data regarding the 57-57 SLE Project at EULAR
Active Biotech, 06/15/09
Active Biotech has presented updated data from a concluded Phase Ib trial of the 57-57 SLE project at the 10th Annual Congress of the European League against Rheumatism (EULAR), an international event for specialists in the field of rheumatology, held in Copenhagen June 10-13. The patients in the Phase Ib trial were treated daily for 12 weeks with 57-57. The maximum tolerable dose was, as earlier communicated, defined at 4.5 mg/day.
Today in Biotechnology...keeping you current
Receive free subspecialty "5-minute updates" via email
Abbott to Acquire Novel Investigational Biologic to Treat Chronic Pain
Abbott, 11/16/09
Position statement of the Portuguese Society of Nephrology on the clinical use of biotechnological drugs in renal patients
Portuguese Journal of Nephrology and Hypertension, 10/12/09
Orally Disintegrating Tablets: The Effect of Recent FDA Guidance on ODT Technologies and Applications
Pharmaceutical Technology, 10/14/09
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
FDA Approves New Test to Aid in the Diagnosis of Rheumatoid Arthritis
Abbott, 10/21/09
Dell Tries to Make an EHR Splash
HealthDataManagement, 11/03/09
Novel agent for treatment of Parkinson's disease - Lu 02-750 - enters Lundbeck's development pipeline
Lundbeck, 11/02/09
Article Search
Sponsor